Gabriel Pardo to Multiple Sclerosis, Relapsing-Remitting
This is a "connection" page, showing publications Gabriel Pardo has written about Multiple Sclerosis, Relapsing-Remitting.
Connection Strength
1.868
-
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017 Dec; 264(12):2351-2374.
Score: 0.573
-
Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. J Neurosci Nurs. 2010 Feb; 42(1):40-6.
Score: 0.338
-
Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022 Jul; 63:103922.
Score: 0.199
-
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Ann Clin Transl Neurol. 2021 03; 8(3):711-715.
Score: 0.182
-
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
Score: 0.174
-
IFN-ß treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015 Mar 01; 194(5):2110-6.
Score: 0.120
-
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15; 341(1-2):22-7.
Score: 0.113
-
A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol. 2011 Mar; 258(3):402-11.
Score: 0.089
-
Arterial compliance in multiple sclerosis: a pilot study. Angiology. 2010 Feb-Mar; 61(1):31-6.
Score: 0.081